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Abstract
Intracellular pathogens have evolved to utilize normal cellular processes to complete their
replicative cycles. Pathogens that interface with proliferative cell signaling pathways risk
infections that can lead to cancers, but the factors that influence malignant outcomes are
incompletely understood. Human papillomaviruses (HPVs) predominantly cause benign
hyperplasia in stratifying epithelial tissues. However, a subset of carcinogenic or “high-risk”
HPV (hr-HPV) genotypes are etiologically linked to nearly 5% of all human cancers. Pro-
gression of hr-HPV-induced lesions to malignancies is characterized by increased expres-
sion of the E6 and E7 oncogenes and the oncogenic functions of these viral proteins have
been widely studied. Yet, the mechanisms that regulate hr-HPV oncogene transcription and
suppress their expression in benign lesions remain poorly understood. Here, we demon-
strate that EGFR/MEK/ERK signaling, influenced by epithelial contact inhibition and tissue
differentiation cues, regulates hr-HPV oncogene expression. Using monolayer cells, epithe-
lial organotypic tissue models, and neoplastic tissue biopsy materials, we show that cell-
extrinsic activation of ERK overrides cellular control to promote HPV oncogene expression
and the neoplastic phenotype. Our data suggest that HPVs are adapted to use the EGFR/
MEK/ERK signaling pathway to regulate their productive replicative cycles. Mechanistic
studies show that EGFR/MEK/ERK signaling influences AP-1 transcription factor activity
and AP-1 factor knockdown reduces oncogene transcription. Furthermore, pharmacological
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inhibitors of EGFR, MEK, and ERK signaling quash HPV oncogene expression and the neo-
plastic phenotype, revealing a potential clinical strategy to suppress uncontrolled cell prolif-
eration, reduce oncogene expression and treat HPV neoplasia.
Author summary
Human papillomavirus (HPV) infections occur in differentiating squamous epithelium
and induce hyperplasia during the viral replicative cycle. Although HPV oncogene expres-
sion is necessary to promote cellular proliferation for viral genome amplification in the
middle epithelial layers, oncogene levels are thereafter suppressed to permit differentia-
tion-induced late gene expression in the uppermost epithelial cells. Yet, the mechanisms
responsible for controlling HPV oncogene expression are not well understood. Here, we
demonstrate that EGFR/MEK/ERK signaling, which is subject to the normal cellular cues
of contact inhibition and epithelial tissue differentiation, is a critical regulator of hr-HPV
oncogene expression. We found that extrinsic activation of ERK overrides cellular control
to promote oncogene expression and the neoplastic phenotype. Many epidemiologically
defined risk factors activate the EGFR/MEK/ERK pathway, suggesting a common mecha-
nism whereby they may promote HPV persistence and disease progression. Lastly, we
show that HPV oncogene transcription and protein expression remain susceptible to
MEK/ERK control in early neoplastic tissues and tumor cells and that targeted inhibition
of MEK/ERK signaling might be exploited therapeutically for HPV-induced infections
and tumors.
Introduction
Over 200 human papillomavirus (HPV) genotypes are recognized and can be grouped as high-
risk (hr) or low-risk based on their ability to cause epithelial lesions with a high or low risk of
malignant progression [1]. Oncogenic HPVs, including hr-HPV types 16, 18, and 31, have
well-documented roles in the development of�99% of cervical cancers [2]. Hr-HPVs also are
implicated in the etiology of cancers at other anogenital sites, and a large subset of oropharyn-
geal squamous cell carcinomas (OP-SCC) [3–5]. In all, hr-HPVs are estimated to be responsi-
ble for�5% of cancers worldwide [3]. Genetic approaches demonstrate that maintained
expression of the hr-HPV E6 and E7 oncoproteins is necessary for the transformed phenotype
in vitro and in vivo [6–8].
The complete replicative cycles of HPVs are complex and dependent on the differentiation
program of stratified epithelium [9]. HPV infection of the basal epithelial cells initiates persis-
tence via extra-chromosomal (episomal) nuclear replication of the circular viral genome. In
the basal and suprabasal epithelial cells, early viral gene transcription is initiated from an early
promoter, and hr-HPV early proteins promote host cell proliferation (E5, E6, E7) and viral
genome amplification (E1, E2, E4) in the middle epithelial layers [10–13]. The hr-HPV E5, E6,
and E7 oncogenes each are required for a productive infection as demonstrated in three-
dimensional (3D) organotypic epithelial tissue cultures [10,11,14]. In uninfected epithelium
and during productive HPV infections (e.g., cervical low-grade intraepithelial lesions [LSIL]),
the suprabasal cells initiate a differentiation program. As infected cells leave the middle epithe-
lial layers, presumably after amplification of viral genomes, early viral gene expression is sup-
pressed; thereafter, expression of the capsid viral genes leads to progeny virion assembly [9].
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Although keratinocyte differentiation cues are well known to activate late viral gene transcrip-
tion [15], their contribution to subduing HPV early gene expression has not been studied.
Thus, despite the fact that hr-HPV oncoproteins can inhibit differentiation, it remains enig-
matic how hr-HPV early transcription is suppressed to reduce oncoprotein expression and
permit differentiation in the middle epithelial layers during the productive HPV replicative
cycle.
In contrast to a productive HPV infection, cervical high-grade intraepithelial lesions
(HSIL) and HPV-positive cancers exhibit sustained expression of hr-HPV oncogenes and loss
of epithelial differentiation in the middle-to-upper epithelial cell layers [12,16–18]. Although
HPV E2 protein can suppress the viral early promoter when hr-HPV genomes are integrated
into host cells, it has not been shown to do so in cells with episomal genomes [19]. Thus, the
driving force behind increased oncogene expression during neoplastic progression is poorly
understood.
The expression and activities of the epidermal growth factor receptor (EGFR) in epithelium
parallel the pattern of HPV oncogene expression in productive HPV infections and early neo-
plasia [16]. EGFR, a receptor tyrosine kinase (RTK), plays a well-recognized role in keratino-
cyte proliferation and epithelium development [20,21]. Dividing keratinocytes in the basal
epithelial layer display the greatest expression and activity of EGFR (i.e., phosphorylated-
EGFR forms) [22], which sustains proliferation [23]. During the program of epithelial differen-
tiation, EGFR expression is downregulated [24,25], and inhibiting EGFR activity blocks prolif-
eration and induces early terminal differentiation of epidermal keratinocytes [26,27].
However, EGFR expression often remains elevated in hyperproliferative skin diseases like pso-
riasis and SCCs, albeit inconsistently in HPV positive SCCs [24,25,28]. Additionally, EGFR
signaling and the levels of phospho-extracellular signal-regulated kinase 1/2 (p-ERK1/2), a
downstream effector of RTKs via the mitogen-activated protein kinase kinase (MEK), increase
during cervical intraepithelial neoplasia (CIN) progression from LSIL to HSIL [29–31]. Never-
theless, a mechanistic link between EGFR-mediated ERK1/2 signaling and HPV oncogene
expression has not been investigated.
A substantive body of research indicates a link and crosstalk between proliferative signaling
by EGFR and hr-HPV oncogene expression. EGF treatment of SiHa cervical cancer-derived
cells led to increased HPV16 E6/E7 mRNA expression and this was dependent upon the pres-
ence of AP-1 transcription factor (TF) binding sites in the viral long control region (LCR)
[32], a noncoding regulatory segment located upstream of the early gene coding region. AP-1
TFs are comprised of either homodimers of Jun proteins (c-Jun, JunB, JunD) or heterodimers
of Jun with the Fos proteins (c-Fos, FosB, Fra-1, Fra-2) that transactivate gene expression by
binding to heptamer consensus (5’-TGA[C/G]TCA-3’) and related sequences [33]. AP-1 TFs
are well-known to be downstream effectors of EGFR and MEK/ERK signaling (reviewed by
[33]), and, importantly, AP-1 binding sites are highly conserved in the LCRs across HPV geno-
types [34]. AP-1 factors c-Fos, c-Jun and JunB were shown to directly mediate LCR-mediated
transcription of hr-HPV types 16, 18, and 31 [35–37]. Additionally, the expression and activity
of AP-1 TFs correlate with HPV oncogene transcription and cervical cancer progression from
LSIL to HSIL [38–41]. These observations imply, but do not explicitly show, that EGFR and
MEK/ERK signaling could be directly involved in promoting HPV oncogene expression, in
addition to stimulating cell proliferation, in productive HPV infections and during cancer
progression.
Despite the apparent, albeit fragmented, link between EGFR and ERK signaling and the
expression of hr-HPV oncogenes, it has not been determined whether EGFR/MEK/ERK sig-
naling has a role in HPV oncogene expression in infected human keratinocytes that maintain
episomal viral genomes and model persistent early neoplastic infections. To this end, we
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investigated the mechanistic interplay between EGFR/ERK signaling and hr-HPV oncogene
expression in epithelial cells and tissues. Our results from clinical lesions, cell cultures, and tis-
sue models show a crucial role for MEK/ERK signaling in regulating hr-HPV oncogene
expression in an epithelial tissue context. Furthermore, our findings reveal the requirement for
MEK/ERK activity as a vulnerability that might be specifically targeted with clinically approved
inhibitors in HPV-induced infections and cancers.
Results
Cervical clinicopathologic characteristics, p-ERK1/2, and p16INK4
expression
We previously showed that p-ERK1/2 overexpression is linked to clinical features of CIN pro-
gression from LSIL to HSIL, and is associated with poor prognosis and decreased disease-free
and overall survival [29]. As the expression of hr-HPV E6 and E7 mRNAs show strikingly sim-
ilar expression patterns and clinical associations with p-ERK1/2 signaling [9,29], we directly
assessed the association between ERK activity and HPV oncogene expression during the tran-
sition of histologically normal cervical epithelia to LSIL and HSIL. In the same cohort of cervi-
cal tissues from patients with CIN lesions, we compared p-ERK1/2 IHC with that of p16INK4
(p16), an established surrogate marker of E7 expression [42]. In normal biopsies p-ERK1/2
expression was present in the lower epithelial layers as previously described in this cohort [29],
whereas p16 expression was not readily observed (Fig 1). Cytoplasmic and nuclear p-ERK1/2
expression was increased in the lower layers and detection of p16 expression followed the
same pattern in the CIN lesions (Fig 1A). p-ERK1/2 expression was progressively up-regulated
from normal to LSIL to HSIL (Fig 1B and S1 Table). Likewise, p16 expression gradually
increased according to the stages of cervical neoplastic progression, from normal tissues
through LSIL and HSIL and strong expression of both p-ERK1/2 and p16 was often coincident
throughout the HSIL tissues (Fig 1 and S1 Table). Furthermore, the combined expression of p-
ERK1/2high/p16high was significantly increased during the transition of normal to LSIL to HSIL
Fig 1. Correlation of p-ERK1/2 and p16INK4 expression in human cervical intraepithelial neoplasia specimens.
(A) Representative IHC staining images of p16INK4 (p16) and p-ERK1/2 in normal, LSIL, and HSIL specimens. Bars
equal 200 μm. (B) Box plot depiction of IHC scores; center tendency and variability. IHC scores for p-ERK1/2 and
p16INK4 expression levels were significantly increased according to disease progression from normal to LSIL to HSIL
(��p< 0.01 and ���p< 0.001 correspond to the non-parametric Kruskal-Wallis/Mann–Whitney U tests). (C) The
combined expression of p-ERK1/2 and p16INK4 was compared among normal, LSIL, and HSIL samples (see S1
Table). The combined expression of p-ERK1/2high and p16INK4high was significantly increased in HSIL specimens
compared to LSIL or normal samples (χ2 test; p< 0.001).
https://doi.org/10.1371/journal.ppat.1009216.g001
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(χ2 test; p< 0.001) (Fig 1C). These data show a strong association between ERK activity and
HPV oncogene expression during HPV-induced CIN progression.
EGF stimulates viral early gene transcription in HPV16(+) human
keratinocytes
There are few, but conflicting reports on the effects of EGF stimulation on HPV oncogene
transcription [32,43]. Thus, to investigate the cause-effect relationship between EGFR/ERK
signaling and HPV oncogene expression we assessed the outcome of EGFR signaling in
human keratinocytes that maintain episomal HPV16 genomes. Two independently-derived,
HPV16 positive (+) cell lines, NIKS-SG3 and NIKS-1K, were developed from the near-diploid
NIKS human keratinocyte cell line [44]. Both HPV16(+) cell lines initiate late virus life cycle
stages when cultured as differentiating 3D-organotypic epithelial tissues, and thus model per-
sistently infected, neoplastic SIL phenotypes [45,46]. To determine how EGF stimulation
affected viral transcription in the proliferative context of episomally-replicating HPV16
genomes, subconfluent NIKS-SG3 cells were treated with 10 ng/ml EGF. HPV RNA levels
were quantified by RT-qPCR targeting unspliced E6 and/or E7 mRNAs, as well as spliced
E1^E4/E5 mRNAs. In each of three independent experiments with proliferating cells, EGF
stimulation for 24h and 48h led to slight (�2-fold) but consistently higher levels of HPV onco-
gene transcripts compared to untreated controls (Fig 2A–2C). Although the combined results
of three independent experiments failed to reach statistical significance, the averaged oncogene
mRNA levels were moderately higher in EGF-treated cells. Increased oncogene mRNA levels
upon EGF stimulation were also observed using RNA in situ hybridization (RNA ISH) to
Fig 2. EGF stimulation results in increased viral transcription in the HPV16(+) NIKS-SG3 cell line. (A-C) Cells
were incubated with (+) or without (Ø) 10 ng/ml EGF for the indicated times. Total RNA was subject to RT-qPCR for
quantification of HPV early transcripts E6 (A), E7 (B) or E1^E4/E5 (C) (primer placement shown in S1 Fig). HPV
mRNA levels were normalized to ribosomal protein 18s mRNA levels and are shown relative to the HPV mRNA levels
in the 24h untreated cells for each experiment. The scatter plot shows the mean and range of the data from three
independent experiments, wherein color-coded symbols show the data from independent experiments. The data were
analyzed using 1-way ANOVA with Dunnett’s T3 multiple comparison test post hoc (not significant [n.s.]). (D-F)
RNA ISH specific for hr-HPV E6/E7 RNAs on cells cultured with 10ng/ml EGF; (G-I) dose-effect of EGF on cells
grown for 24h with or without added EGF (G-I). Bars equal 100 μm.
https://doi.org/10.1371/journal.ppat.1009216.g002
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detect polycistronic E6/E7-containing transcripts. Consistent with RT-qPCR data, EGF stimu-
lation led to an increase in HPV16 E6/E7 RNA levels (Fig 2G–2I). The specificity of the RNA
ISH was confirmed with controls: no positive RNA ISH signals were observed in the unin-
fected NIKS parental cells (Fig 2D), whereas the two HPV16(+) NIKS-derived cell lines were
positive by RNA ISH (Fig 2E and 2F). Curiously, the time-course EGF stimulation experi-
ments suggested that HPV early gene expression was negatively affected by increasing cell den-
sity. As the cells become more confluent from 24h to 48h, the HPV E6, E7, and E1^E4/E5
mRNA levels tended to decrease (Fig 2A–2C). These results indicate that EGF exposure has
only a modest positive effect on HPV early gene transcription in proliferating cells with repli-
cating episomal viral genomes. However, the findings also suggest that increasing cell density
is a potential confounding factor in studying HPV oncogene expression and requires more
directed investigation.
Cell confluence and contact inhibition negatively regulate HPV
oncoprotein expression
To determine the impact of cell confluence on viral gene expression in a controlled manner,
we seeded replicate cultures of HPV16(+) NIKS-derived cell lines at equal cell densities and
analyzed their growth and viral gene expression patterns in serum-containing medium lacking
exogenous EGF. We found the NIKS-1K cell line grew past confluence and continued to pro-
liferate before demonstrating contact inhibition of cell growth (Fig 3A). This is consistent with
NIKS-1K data reported by Isaacson Wechsler et al., who also showed NIKS-1K cells give rise
to an HSIL phenotype when grown as organotypic epithelial tissues [46]. In contrast, the
NIKS-SG3 cell line, which demonstrates an LSIL phenotype in organotypic epithelial tissue
culture [45], became contact inhibited and ceased dividing�24 h earlier than NIKS-1K cells
(Fig 3A). We assessed the expression of the E7 oncoprotein in these cells harvested at increas-
ing cell densities. Whereas the E7 oncoprotein was detectable in preconfluent cultures of both
HPV16(+) NIKS cell lines, E7 protein levels decreased significantly as the cell cultures became
contact inhibited (Fig 3B and 3C). Interestingly, NIKS-SG3 cells, whose proliferation plateau
was reached more quickly than NIKS-1K cells, lost E7 expression at a significantly more rapid
rate, whereas slower loss of E7 expression post confluence correlated with reduced contact
inhibition in NIKS-1K cells (Fig 3A–3C). These results raised the possibility that altered cell
signaling linked to cellular contact inhibition is important for the regulation of HPV oncopro-
tein expression.
HPV oncogene expression and EGFR/MEK/ERK activity diminish as cells
grow to higher densities
There are well-established roles for cell confluency and contact inhibition in suppressing RTK
signaling in monolayer cell cultures (reviewed in [47]). Curto et al. showed global tyrosine
phosphorylation and EGFR activity is reduced in non-tumorigenic cell lines as cell densities
increase [48]. Thus, we determined the effects of increasing cell density on cellular tyrosine
phosphorylation and EGFR activity in HPV(+) cell lines that maintain episomal viral genomes
of hr-HPV genotypes 16, 18, or 31 derived by both transfection and from clinical CIN lesions.
To rule out time in culture as a variable, we seeded equal numbers of cells into dishes with
decreasing surface areas in medium lacking exogenous EGF (S2A Fig). Similar to the results
reported by Curto and coworkers, tyrosine phosphorylation decreased with increasing cell
density in each of the HPV(+) cell lines after 24h in culture (S2B Fig).
Concomitant with decreased global tyrosine phosphorylation and increasing cell density,
EGFR/MEK/ERK signaling, measured by p-EGFR and p-ERK1/2, was suppressed in all cells
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examined (Figs 3D–3F and S2D). Although total levels of EGFR and ERK1/2 were unaltered
or slightly diminished by increasing cell density of NIKS and the two HPV16(+) NIKS cell
lines, both p-EGFR (Y845) and p-ERK1/2 were suppressed (Fig 3D–3F). Similar results were
seen in the CIN 1-derived HPV16(+) W12-E cell line, the HPV18(+) NIKS-H18 cell line, and
the CIN 1-derived HPV31(+) CIN-612 9E cell line, (S2D Fig).
The suppression of EGFR/MEK/ERK signaling with increasing cell density correlated with
reduced HPV oncoprotein levels and their mRNA transcripts. Increasing cell density led to
reduced E7 protein levels in HPV16(+) and HPV18(+) cells (Figs 3E, 3F, S2D and S2E).
Although challenging to detect in most HPV infected cells, E6 protein levels were also reduced
following increasing cell density (S2D and S2E Fig). Lacking antibodies that detect HPV31 E6
and E7 proteins, we were unable to correlate the reduced EGFR activity with HPV31 oncopro-
tein expression (S2C Fig). Transcriptional suppression of HPV E6 and E7 mRNAs closely fol-
lowed the cell-regulated decreases in EGFR/MEK/ERK signaling in each HPV(+) cell line
tested (Figs 3G, 3H, S2F and S2G). These data suggest that HPV oncogene transcription is
closely tied to EGFR/MEK/ERK signaling.
Fig 3. HPV oncoprotein expression is negatively regulated by increasing cell confluence and loss of EGFR/ERK signaling. (A)
Growth curves constructed by seeding 1.5x106 cells in 21cm2 plates and counting cells every 24h over 168h (n = 2; error
bars = SD). Pre-confluent and confluent cell cultures (denoted as “P” and “C”, respectively) were defined by visual inspection of
two biological replicates. (B) Cells were seeded as in (A) and proteins extracted when the cells were 70% (pre-) confluent (P),
100% confluent (C), 24h after reaching confluence (+24), and 72h after confluence (+72), corresponding to times indicated in (A).
Protein lysates (25μg/lane) analyzed by SDS-PAGE and immunoblot (IB). (C) Densitometry analyses on IB data from two
biological replicates as in (B). Box plots represent the median and range of the relative levels of HPV16 E7 protein for each cell
density compared to the pre-confluent samples. Analyses included the random effects linear regression model with random slope,
quadratic time (F = 521.11, p<0.0001 for time linear term and F = 226.02, p<0.0001 for quadratic time term), and interaction
effect (F = 17.53, p = 0.0007 for the interaction term). (D-H) In parallel, plates of decreasing surface area (21cm2, 9.0cm2 and
4.6cm2) were seeded with 1.25x106 cells, grown for 24h. (D-F) Protein lysates collected 24h post seeding, subjected to SDS-PAGE
and IB. (G, H) Total RNA isolated 24h post seeding subjected to RT-qPCR targeting E7 mRNAs, normalized to ribosomal
protein18s mRNA levels and lowest cell density sample. Scatter plots represent mean and range of the data, which were analyzed
by 1-way ANOVA and Dunnett’s T3 multiple comparison test (�p<0.05, ��p<0.01, ���p<0.001).
https://doi.org/10.1371/journal.ppat.1009216.g003
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Notably, direct comparisons revealed that HPV16(+) NIKS cells consistently showed mod-
erately higher p-EGFR and p-ERK1/2 levels than parental, uninfected NIKS cells (Fig 3D–3F),
but proliferating cells demonstrated similar plasma membrane levels of EGFR (S2C Fig).
These data suggest that persistent HPV infection can augment EGFR/ERK signaling without
substantially altering total EGFR expression. Yet importantly, these non-transformed HPV(+)
cells remained responsive to the growth inhibitory cues of cell contact inhibition, suggesting
that HPV oncoproteins do not dominate EGFR/MEK/ERK activities in these cells. Rather,
these data indicate that EGFR/MEK/ERK signaling governs control over hr-HPV oncogene
expression in HPV-infected cells with early neoplastic phenotypes.
Extrinsic EGFR stimulation overrides contact inhibition, MEK/ERK
signaling suppression and HPV oncogene expression in high-density cell
populations
Stimulation with EGFR ligands is reported to restore EGFR signaling in contact inhibited epi-
thelial cells [49–51]. Thus, we seeded cells at high density and cultured overnight. One set of
cells was untreated and the second was exposed to 10 ng/mL EGF for 24h. As compared to
unstimulated cells in the confluent state, EGF stimulation re-activated EGFR signaling along
with increased E7 oncoprotein expression in each of the cell lines (Fig 4). Lacking specific anti-
bodies that can detect HPV31 E7, we detected p16 as a surrogate of E7 protein induction in
CIN-612 9E cells (Fig 4B, lanes 7–8). In each HPV(+) cell line, increases in oncoprotein
expression were mirrored by increased oncogene mRNA levels (Fig 4C–4E). The EGFR
ligands amphiregulin (AREG), transforming growth factor alpha (TGF-α), and heparin-bind-
ing EGF (HB-EGF) also stimulated E7 protein expression in confluent HPV(+) cells (Fig 4F
and 4G). Thus, extrinsic EGFR stimulation rescues contact inhibition-mediated EGFR/MEK/
ERK suppression of signaling to stimulate HPV oncogene expression. In total, these results
indicate that active EGFR signaling promotes HPV oncogene expression independent of cell
density, hr-HPV genotype, or cell line background.
MEK/ERK signaling is the dominant pathway influencing HPV oncogene
expression
EGFR signaling can activate the MEK/ERK, PI3K/AKT, PKC, and p38 MAPK pathways,
which promote cellular proliferation, survival, and/or migration. To determine whether the
regulation of oncogene expression by EGF stimulation of HPV(+) cells was primarily depen-
dent upon MEK and ERK signaling downstream of EGFR, we performed a dose-escalation
experiment using small molecule drug inhibitors. EGFR was targeted with erlotinib, a revers-
ible, ATP-competitive inhibitor of EGFR tyrosine phosphorylation [52]. MEK1/2, the ERK1/2
kinase, was selectively inhibited with trametinib [53], and SCH772984 was used as a selective
inhibitor that prevents ERK1/2 phosphorylation and activity [54]. High density NIKS-SG3
cells were grown in the presence of increasing drug doses for 8h prior to EGF stimulation.
Similar to data shown in Fig 4, when compared to unstimulated cells, EGF treatment strongly
induced p-EGFR, p-ERK/1/2 and E7 expression (Fig 5A–5C, compare lanes 1 and 2). We
found that each drug inhibited its target in the presence of EGF stimulation, converging in
dose-dependent p-ERK1/2 suppression (Fig 5A–5C, lanes 3–6). In each case suppression of
ERK1/2 phosphorylation closely mirrored the dose-dependent decrease in E7 protein levels
(Fig 5A–5C, lanes 3–6), and each drug treatment also resulted in strong suppression of HPV
oncogene transcription (Fig 5D). Our findings that separate inhibitors targeting EGFR, MEK
or ERK signaling led to a dose-dependent suppression of p-ERK1/2 with concomitant
decreases in HPV oncogene expression minimizes the possibility that off-target drug effects
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contributed to oncogene regulation. Similarly, W12-E cells treated with the MEK inhibitor,
trametinib responded with suppressed p-ERK1/2 and E7 levels; p53 levels increased with tra-
metinib treatment suggesting that E6 protein expression was reduced (Fig 5E). Likewise, HPV
oncogene transcription was suppressed in W12-E cells treated with the MEK inhibitor (Fig
5F). Together, these results indicate that MEK/ERK signaling downstream of EGFR is a crucial
node regulating hr-HPV oncogene transcription and oncoprotein expression.
Due to the frequent activation of the PI3K/AKT pathway in HPV positive cancers [55–57],
we evaluated whether EGF stimulation of this pathway contributed to E7 oncoprotein expres-
sion in cells maintaining episomal HPV genomes. Briefly, W12-E cells were grown at high
density, treated for 48h with increasing doses of BYL719, a selective p110α inhibitor, then
stimulated with EGF. Whereas the highest concentration of BYL719 inhibited phosphorylation
Fig 4. EGFR ligands rescue cell density-dependent suppression of EGFR/MEK/ERK signaling and HPV oncogene
expression in HPV16(+) and HPV31(+) cells. (A-E) Cells were seeded at high cell density (1.3 x 105 cells/cm) and
allowed to attach overnight; cells were then treated with or without 10 ng/ml EGF for 24h before harvest. (A,B)
Proteins (25 μg) subject to SDS-PAGE and IB. (B) In lanes 1–6, E7 proteins were detected; lacking antibodies to
HPV31 E7 protein, p16 was detected as an E7 surrogate (lanes 7–8). (C-E) Total mRNAs extracted from replicate
cultures were subjected to RT-qPCR targeting HPV oncogene mRNA; cDNA levels were normalized to ribosomal
protein 18s mRNA levels and unstimulated sample. Scatterplots represent the mean and range of the data as analyzed
by Welch’s t-test (�p<0.05). (F) High density cells were treated with 10 ng/ml each of EGF, AREG or TGF-α for 48h;
proteins were subject to SDS-PAGE and IB. (G) Cells seeded at a high cell density were treated 24h with increasing
concentrations of HB-EGF; proteins were subject to SDS-PAGE and IB.
https://doi.org/10.1371/journal.ppat.1009216.g004
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of AKT, this did not hinder the rescue of viral oncoprotein expression (S3 Fig, lane 6). These
data suggest that within the context of contact inhibition, the PI3K/AKT pathway does not
play a substantive role in regulating hr-HPV oncogene expression downstream of EGFR.
MEK/ERK signaling promotes AP-1 transcription factor activity to activate
HPV oncogene transcription
As AP-1 TFs are activated by serum and growth factor stimulation via ERK1/2, among other
kinases [33,58,59], we assessed the activity of AP-1 TFs in nuclear extracts from W12-E cells.
Thus, we determined which AP-1 TFs were activated under conditions that enhance and sup-
press HPV oncogene transcription. Levels of active AP-1 TFs were compared among cells
grown at high-density to suppress p-ERK1/2 activity and oncogene transcription, high-density
cells stimulated for 14 h with EGF to increase both, and cells stimulated with EGF following
treatment for 8h in the presence of MEK inhibitor, trametinib, to specifically inhibit p-ERK1/2
Fig 5. HPV oncogene expression is dependent upon EGFR/MEK/ERK activity in monolayer cell cultures. (A-C)
Contact inhibited SG3 cells were grown in the presence of increasing concentrations of erlotinib, trametinib or
SCH772984 for 8h prior to EGF stimulation. Protein lysates were collected 14h after EGF stimulation and subject to
SDS-PAGE and IB. (D) Cells seeded at low density (2.3 x104 cells/cm) were treated with 1μM erlotinib, 10nM
trametinib, or 1μM SCH772984 for 24 hours. Total RNAs extracted from replicate cultures were subjected to RT-qPCR
for HPV transcripts and levels were normalized to ribosomal protein 18s mRNA levels. Vehicle treated (DMSO) was
set to one in each experiment and the data were analyzed by 1-way ANOVA and Dunnett’s T3 multiple comparison
test (�p<0.05 or ��p<0.01). (E-F) W12-E cells were seeded at low density (3.12 x104 cells/cm) treated with 10 nM or 50
nM trametinib for 24 hours. (E) Protein (50 μg) was subject to SDS-PAGE and IB. (F). Total RNAs extracted from
replicate cultures were subjected to RT-qPCR for HPV transcript and normalized to ribosomal protein 18s mRNA
levels. Vehicle treated (DMSO) was set to one in each experiment and the data was analyzed by 1-way ANOVA with
Dunnett’s T3 multiple comparison post hoc test (�p<0.05, ��p<0.01, ���p<0.001).
https://doi.org/10.1371/journal.ppat.1009216.g005
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signaling (Fig 6A). We found that activity of c-Fos, Fra-1, JunB, and JunD were specifically
increased with p-ERK1/2 signaling, whereas the activity of FosB and c-Jun were not apprecia-
bly affected by p-ERK1/2 stimulation. Previous studies showed c-Fos, c-Jun and JunB directly
mediated LCR-mediated transcription of hr-HPVs [35–37,60], whereas JunD and Fra-1
appeared to negatively impact HPV transcription or were not involved [38,39,61,62]. We
therefore assessed whether knockdown of c-Fos and JunB, whose activity was activated by p-
ERK1/2 signaling, and c-Jun, which was not p-ERK1/2 responsive, influenced the expression
Fig 6. AP-1 transcription factors regulate HPV oncogene expression. (A) W12-E cells were seeded at high density
and grown for 8h in the presence of DMSO or 50 nM trametinib prior to EGF stimulation. Nuclear extracts were
collected 14h after EGF stimulation and assayed for the levels of each active AP-1 factor. (B-G) W12-E cells were serum
starved for 4h prior to transfection with commercially available siRNA pools targeting FOS, JUN or JUNBmRNAs or
non-targeting (NT) control siRNAs; these mRNAs encode the proteins c-Fos, c-Jun, or JunB, respectively. (B,D,F)
Total mRNAs were extracted at 24h post transfection and subjected to RT-qPCR to quantify the AP-1 mRNAs and
HPV E7 oncogene mRNAs. cDNA levels were normalized to those of ribosomal protein 18s and the values for NT
siRNA transfected samples were set to one in each experiment. (C,E,G) At 24h post transfection, medium was replaced
with serum-containing medium prior to harvesting for RNA and protein analyses at 48 post transfection Scatterplots
represent the mean and range of the RT-qPCR data, which were analyzed by an unpaired Welch’s t-test (�p<0.05,
��p<0.01, ���p<0.001). Protein lysates collected 48h post transfection were subjected to SDS-PAGE, IB and
densitometry. Values directly below each lane represent the protein levels normalized to the NT siRNA transfected
samples in each experiment.
https://doi.org/10.1371/journal.ppat.1009216.g006
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of HPV oncogenes in cells maintaining episomal HPV genomes. HPV16(+) W12-E cells were
serum starved to promote transfection and minimize ERK1/2 signaling. Cells were assayed at
either 24h post transfection or at 48h post transfection following 24h of stimulation with
medium containing 10% FBS to promote p-ERK1/2 activity. At 24h post transfection, cells
receiving siRNAs to c-Fos-, c-Jun-, or JunB-encoding mRNAs showed an average AP-1 target
mRNA knockdown of�50% compared to those transfected with non-targeting siRNAs (Fig
6B, 6D and 6F). At 24h post transfection E7 mRNAs were diminished significantly in cells
with reduced c-Fos-encoding mRNAs (Fig 6B). However, both c-Fos- and E7-encoding
mRNA levels rebounded and E7 protein levels were not appreciably altered in the presence of
p-ERK1/2 at 48 h post transfection, following 24 h of serum stimulation (Fig 6C). Knockdown
of c-Jun- and JunB-encoding mRNAs and their proteins at 48h post transfection in the pres-
ence of p-ERK1/2 were each accompanied with reduced E7 transcript and protein levels (Fig
6E–6G). Although it is unclear why the c-Fos-encoding mRNA knockdown was short lived
upon serum stimulation and p-ERK1/2 activation, oncogene mRNA levels followed those of
the AP-1 factors. These data are consistent with the idea that AP-1 TFs are needed for the
expression of the HPV oncogenes and that c-Fos and JunB control oncogene transcription
downstream of MEK/ERK signaling.
EGFR/MEK/ERK signaling regulates HPV oncogene expression in
organotypic epithelial tissues
To assess whether EGFR/MEK/ERK activation was relevant for the regulation of HPV onco-
gene expression during the differentiation-dependent viral replicative cycle, we examined
Fig 7. EGFR and MEK signaling regulates HPV oncogene expression in 3D-organotypic epithelial tissue models.
Representative images of organotypic epithelial tissues from NIKS-SG3 cells grown at the air-liquid interface for 8 days
prior to treatment with 10 ng/ml EGF or 10 nM trametinib every second day. FFPE tissues harvested on day 14 were
sectioned and stained: (A, E, I) H&E; (B, F, J) IHC for p-ERK1/2; (C, G, K) RNA ISH (brown); (D, H, L) IHC for p16.
Broken lines underscore the basal cell layer.
https://doi.org/10.1371/journal.ppat.1009216.g007
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organotypic epithelial tissues of NIKS-SG3 and W12-E cells (Figs 7 and 8). Organotypic
NIKS-SG3 and W12-E tissues grown in the absence of exogenous EGF demonstrated stratifi-
cation as seen by an organized basal layer and an uppermost cornified layer, (Figs 7A and 8A).
Nuclear p-ERK1/2 and E6/E7 mRNA were detected predominantly in the basal layer cells in
the NIKS-SG3 tissues which demonstrate an LSIL phenotype (Fig 7B and 7C). W12-E organo-
typic tissues exhibited a dysplastic phenotype with increased nuclear p-ERK1/2 staining and
E6/E7 mRNA detection higher throughout the tissue (Fig 8B and 8C). As E6 and E7 antibodies
fail to detect the oncoproteins in FFPE sections, we stained the tissues for the E7 surrogate
p16INK4 (p16) [42]. In agreement with the E6/E7 RNA ISH results in untreated epithelial tis-
sues, p16 staining was strongest in the basal layer with lightly positive scattered cells in the
intermediate epithelial layers of the NIKS-SG3 tissue and strongly positive cells in the W12-E
intermediate tissue layers (Figs 7D and 8D). This concordance of E6/E7 RNA ISH and p16
localization and expression are consistent with data from HPV16-infected lesions [63]. In con-
trast, NIKS-SG3 and W12-E epithelial tissues stimulated with EGF for the last 6 days of growth
demonstrated a differentiated but hyperplastic epithelium, and concomitantly, increased levels
of p-ERK1/2, E6/E7 mRNAs, and p16 were observed throughout the basal and suprabasal cells
(Figs 7E–7H and 8E–8H). Inhibition of MEK signaling with trametinib preserved epithelial
differentiation but strongly suppressed p-ERK1/2 in both NIKS-SG3 and W12-E tissues (Figs
7I–7J and 8I–8J). In parallel, E6/E7 mRNAs and p16 were profoundly reduced (Figs 7K–7L
and 8K–8L). In total, the monolayer and 3D-epithelial tissue data indicate that EGFR/MEK/
ERK signaling is a crucial regulator of epithelial proliferation and of hr-HPV oncogene
Fig 8. EGFR and MEK signaling regulates HPV oncogene expression in 3D-organotypic epithelial tissue models.
Representative images of organotypic epithelial tissues from W12-E cells grown at the air-liquid interface for 8 days
prior to treatment with 10 ng/ml EGF or 10 nM trametinib every second day. FFPE tissues harvested on day 14 were
sectioned and stained: (A, E, I) H&E; (B, F, J) IHC for p-ERK1/2; (C, G, K) RNA ISH (red); (D, H, L) IHC for p16.
Broken lines underscore the basal cell layer.
https://doi.org/10.1371/journal.ppat.1009216.g008
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expression from episomally-replicating viral genomes during a productive hr-HPV infection
in epithelium.
EGFR/MEK/ERK regulates HPV oncogene expression in HPV(+) cancer
cell lines cultured in monolayer and as organotypic tissues
The experiments above demonstrated that HPV oncogene expression in the context of
episomal genome replication is dependent upon EGFR/MEK/ERK signaling. However, many
HPV-related human cancers harbor integrated viral genomes expressing E6 and E7. Although
HPV genome integration disrupts the viral life cycle, the viral LCR invariably remains intact
upstream of the viral early promoter that directs oncogene expression [64,65]. SiHa cervical
SCC-derived cells containing integrated HPV16 genomes were shown to respond to EGF stim-
ulation with enhanced E6/E7 mRNA expression dependent upon the viral LCR [32]. Thus, we
hypothesized that other HPV(+) cancer cell lines would remain EGFR-signaling dependent.
Rather than using cervical cancer cell lines with long and poorly defined culture history, we
tested this hypothesis using the UM-SCC-47 cell line, which we obtained from the lab from
which it was established. The UM-SCC-47 cell line was derived from the primary tumor of a
moderately differentiated OP-SCC and harbors integrated HPV16 genomes [66]. The
UM-SCC47 cell line was treated with increasing concentrations of trametinib for 24 hours.
MEK inhibition resulted in dose-dependent suppression of p-ERK1/2, E7, and p16 protein
expression (Fig 9A). As E6 protein expression was difficult to detect, we assayed p53 protein
expression as a surrogate of E6 activity. We found that p53 levels increased concomitant with
increasing trametinib concentrations, implying that E6 protein expression was decreased with
MEK inhibition (Fig 9A). Furthermore, the reduction in HPV oncoprotein levels in response
to MEK inhibition corresponded to decreased levels of E6 and E7 mRNAs (Fig 9B) similar to
the outcomes in HPV(+) non-tumorigenic cell lines (Fig 5). Although p-ERK1/2 levels were
nearly undetected at the highest doses of trametinib, E7 and p16 remained detectable. This
suggests a mechanism in addition to MEK/ERK signaling may contribute to oncogene expres-
sion in these cells.
When UM-SCC-47 cells were cultured as organotypic epithelial tissues, the untreated tis-
sues appeared partially differentiated, with a distinct uppermost cornified layer (Fig 9Ci).
Nuclear p-ERK1/2, E6/E7 mRNAs, and p16 protein were confined to the middle and lower
epithelial layers (Fig 9Cii–iv), suggesting an intact stratification program. However, EGF treat-
ment led to epithelial proliferation resulting in overgrowth resembling hyperplasia and aber-
rant stratification; basal-like cells present at the apical tissue surface and an inverted cornified
layer are suggestive of keratin pearls, a morphology consistent with SCC [67]. Likewise, p-
ERK1/2, E6/E7 mRNAs, and p16 were increased in the non-cornified cells, including those at
the apical surface (Fig 9Cv–viii). In contrast, trametinib-treated UM-SCC-47 epithelial tissues
demonstrated a thickened apical cornified layer and greatly reduced p-ERK1/2 staining (Fig
9Cxi–x). Concurrently, the levels of E6/E7 transcripts and p16 protein staining were largely
reduced (Fig 9Cxi–xii). Together with the findings in HPV(+) SiHa and UM-SCC-47 SCC cell
monolayers, these findings demonstrate that the EGFR/MEK/ERK signaling pathway regulates
HPV oncogene expression in the context of tissues expressing oncogenes from integrated
HPV genomes.
Discussion
Deregulated and maintained hr-HPV E6 and E7 oncogene expression is a central feature of
HPV-induced pathogenesis and cancer progression. Numerous studies have shown that
genetic suppression of oncogene expression results in cell cycle arrest, apoptosis, and tumor
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suppression [68–71]. Thus, these viral oncogenes are regarded as ideal therapeutic targets.
Here, we aimed to understand the normal regulation of hr-HPV early gene expression in the
context of epithelial infection, with a goal of revealing mechanisms underlying the loss of
oncogene regulation that accompanies and is thought to promote neoplastic progression. Our
Fig 9. EGFR and MEK signaling regulates HPV oncogene expression in an HPV(+) OP-SCC cell line and 3D-
organotypic epithelial tissues. (A-B) In parallel experiments, UM-SCC-47 cells were seeded at a low cell density for
16h before treating with increasing concentrations of trametinib or vehicle (0.1% DMSO) for 24h. (A) Protein lysates
(25 μg) were analyzed by SDS-PAGE and IB. (B) Total RNAs extracted from replicate cultures subjected to RT-qPCR
for HPV transcripts and normalized to ribosomal protein 18s mRNA levels. Vehicle treated (DMSO) values were set to
one in each experiment and the data were analyzed by 1-way ANOVA with Dunnett’s T3 multiple comparison post
hoc test (�p<0.05). (C) Organotypic cultures were grown for 8 days prior to treatment with 10 ng/ml EGF or 10 nM
trametinib every second day. FFPE tissues harvested on day 14 were sectioned and stained: (i, v, ix) H&E; (ii, vi, x) IHC
for p-ERK1/2; (iii, vii, xi) RNA ISH (brown chromogen); (iv, viii, xii) IHC for p16. Broken lines underscore the basal
cell layer.
https://doi.org/10.1371/journal.ppat.1009216.g009
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results show that hr-HPVs rely on the EGFR/MEK/ERK signaling pathway to both activate
and suppress oncogene expression depending upon the cellular and tissue context (Fig 10).
We investigated hr-HPV-infected cells and organotypic tissues that express viral genes
from their native promoters in episomally-replicating viral genomes and show that hr-HPV
oncogene transcription is regulated by contact inhibition, a cellular process in place to con-
strain proliferative signaling. Cellular contact inhibition is a mechanism that safeguards tissue
homeostasis by uncoupling cell proliferation from mitogenic stimulation [72]. Loss of contact
inhibition leads to hyperplasia in vivo and enables malignant progression by imparting a devel-
oping cancer cell with a propensity for unrestricted expansion [73]. Although the mechanisms
controlling contact inhibition are incompletely defined, RTK signaling is regarded as an
important regulator [48]. We focused on the role of EGFR/MEK/ERK signaling, as EGFR sig-
naling is suppressed when cells become contact inhibited [48,50]. Specifically, we show that
when cellular contact inhibition mechanisms suppress EGFR/MEK/ERK signaling, HPV
oncogene transcription is concomitantly reduced. Furthermore, we find that EGFR ligand
stimulation of high-density cells rescues ERK activation, temporarily overcomes contact inhi-
bition, and promotes HPV oncogene expression. Thus, our data emphasize roles for EGFR
and ERK signaling in both of these processes.
We also show in the context of contact inhibition that ERK signaling enhances the activity
of the AP-1 TFs c-Fos, Fra-1, JunB and JunD without altering FosB or c-Jun activities. Never-
theless, knockdowns confirmed that c-Jun, as well as the p-ERK1/2-inducible activities of c-
Fos and JunB contribute to oncogene transcription in the context of replicating HPV genomes,
Fig 10. Model of the Proposed Mechanism of hr-HPV Oncogene Regulation by the MEK/ERK Signaling Pathway.
A working model depicting the coordination of MEK/ERK signaling and hr-HPV E6/E7 oncoprotein expression
leading to progressive loss of differentiation in early to late hr-HPV(+) neoplastic progression (adapted from [27]). (A)
EGFR/MEK/ERK signaling in the basal layer is important for hr-HPV oncogene expression, which feeds back into
enhancing ERK1/2 signaling and dampening terminal differentiation. In contrast, suppressed EGFR/MEK/ERK
signaling in the suprabasal layers leads to reduced E6/E7 oncogene expression, permitting epithelial differentiation and
expression of hr-HPV late proteins in LSIL. (B) Consistent with our data and reports that EGFR signaling and levels of
p-ERK1/2 increase concomitant with HPV oncogene expression during progression from LSIL to HSIL, we find EGFR
stimulation enhances E6/E7 oncogene expression. Our data predict that shifting the balance toward increased ERK1/2
signaling in suprabasal layers would cause increased E6/E7 oncogene expression and further loss of differentiation,
fostering heightened neoplastic phenotypes in HSIL. Greater p-ERK1/2 signaling may result from cell-intrinsic
alterations in upstream activators of ERK, or from cell-extrinsic factors often epidemiologically considered as risk-
factors with hr-HPV infections progressing to HSIL and cancers. See the Discussion for specifics on how estrogen,
tobacco smoke, nitric oxide, epithelial wounding and Chlamydia trachomatis infection (infx.) contribute to enhanced
p-ERK1/2 signaling in the context of an hr-HPV infection and may serve to enhance cellular transformation and
neoplastic progression.
https://doi.org/10.1371/journal.ppat.1009216.g010
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consistent with reductionist studies using LCR-driven reporter genes [35,36,60]. As active c-
Jun levels remained relatively high in cells despite suppressed p-ERK1/2 signaling and onco-
gene expression, this implies that c-Jun heterodimers with c-Fos and/or JunB or c-Fos and
JunB heterodimers may be involved in HPV oncogene transcription regulation under these
conditions. Our data showing EGFR/ERK signaling to c-Fos, JunB and JunD activation are
also consistent with reports that the expression of these AP-1 factors increases substantially in
HPV(+) cervical cancers and cancer cell lines [38,39,62].
Our findings in organotypic epithelial tissue models and clinical cervical lesions provide a
mechanistic link between the E6/E7 mRNA expression patterns observed in productive HPV
(+) infections in vivo [9] with the well-characterized signaling patterns for EGFR and ERK in
epithelia. EGFR plays a crucial role in normal epidermal development and physiology [74,75]
with expression primarily localized to the undifferentiated basal and lower suprabasal layers
[24,25]. EGFR expression is lost as cells exit the basal layers and this activity is accompanied by
differentiation and loss of proliferation [26]. Patterns of p-ERK1/2 expression mirror those of
EGFR in epithelia [76]. Herein we show the direct connection between the spatial expression
of E6/E7 mRNAs (and the E7 surrogate, p16) and p-ERK1/2 signaling, consistent with the idea
that EGFR/MEK/ERK signaling drives HPV oncogene expression in hr-HPV-infected epithe-
lia (Fig 10A). Isaacson Wechsler et al. demonstrated positive correlations amongst increased
hr-HPV E6 and E7 oncoprotein expression, the loss of contact inhibition, and more severe
hyperplasia and neoplastic transformation [46]; our work herein corroborates and extends
their observations. Specifically, they found that cells expressing higher E6 and E7 protein levels
displayed decreased contact inhibition in monolayer cultures, and similarly produced more
severe neoplastic phenotypes (HSIL-like) mirroring reduced contact inhibition in organotypic
epithelial tissues. Additionally, they showed that cells expressing lower oncoprotein levels were
more readily contact inhibited in monolayer and yielded mildly neoplastic (LSIL) phenotypes
in 3D-tissue cultures. Our work supports and deepens mechanistic insight by showing that
EGF stimulation concomitantly enhances both oncogene expression and the severity of the
neoplastic phenotype in 3D-epithelial tissues. Together, these studies underscore the intimate
link between oncogene expression and neoplastic progression, and our data further show that
EGFR/MEK/ERK signaling is central to regulating these phenotypes.
Previous work indicates that hr-HPV oncoproteins, when ectopically over-expressed exper-
imentally or in cancer-derived cells, augment EGFR signaling. For example, hr-HPV E6 and
E7 each reportedly upregulate EGFR expression at the genomic level [77,78]. Hr-HPV E5 over-
expression increases EGFR recycling to the cell surface after activation-induced EGFR inter-
nalization [79–82]. However, no prior studies have determined whether HPV oncoproteins
influence EGFR signaling during an HPV infection when expressed in the context of replicat-
ing viral genomes. Given our finding that EGFR/MEK/ERK signaling promotes HPV onco-
gene expression, one might expect a progressive feed-forward loop to ensue in an HPV lesion
whereby oncoproteins enhance EGFR signaling, which stimulates increased oncogene expres-
sion, and so on. However, our studies clearly show that the HPV(+) cells we studied, including
non-transformed cells and the UNM-SCC-47 cancer cell line, remain responsive to the growth
inhibitory cues of cell contact inhibition and epithelial tissue stratification/differentiation.
These findings indicate that HPV oncoproteins do not dominate EGFR/MEK/ERK activities,
but that EGFR/MEK/ERK signaling governs control over hr-HPV oncogene expression. These
data underscore the importance of studying the functions of viral oncoproteins expressed
from their natural promoters and within the context of other viral proteins.
In contrast to our findings, a few prior reports found some cell lines responded to EGFR
stimulation with decreased E6/E7 transcription [32,43,83]. However, those studies relied on
artificial promoter/enhancers and/or used cells with HPV genomic fragments that might
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impede important oncoprotein-cell signaling crosstalk and could account for the different out-
comes. It is also possible that EGFR-independent ERK signaling pathways can influence HPV
oncogene expression. Such situations may arise during the development of HPV(+) cancers
that have mutations in PIK3CA (or downstream effectors) and/or become refractory to EGFR
or PI3K inhibitors, which we and others reported can lead to MEK/ERK stimulation via other
RTKs [84–87].
Herein, we show the direct correlation amongst clinical features of cervical neoplastic trans-
formation, p-ERK1/2 levels, and the E7 surrogate, p16. This consolidates data from prior stud-
ies showing both increased EGFR and p-ERK1/2 signaling with HPV(+) CIN grade [29,31],
and reports of paralleling increases in hr-HPV E6 and E7 mRNA levels during neoplastic pro-
gression [9]. These findings prompt us to speculate that dysregulation of EGFR and/or MEK/
ERK signaling promotes increased hr-HPV oncogene expression during CIN lesion progres-
sion to cancer (Fig 10B). MEK/ERK signaling, whether induced by extrinsic ligand activation
of EGFR other RTKs or intrinsic genetic mutations in upstream ERK activators may be a key
driving force in neoplastic progression of hr-HPV(+) lesions by both promoting proliferation
and enhancing oncogene expression. Our data suggest that hr-HPVs, and possibly all epithe-
lial-tropic papillomaviruses, have evolved to exploit the MEK/ERK pathway to regulate their
productive replicative cycles. As EGFR/MEK/ERK signaling decreases during normal differen-
tiation, this both suppresses oncogene expression and promotes epithelial differentiation
essential for late viral gene expression (Fig 10A). Yet, this MEK/ERK regulation can be a dou-
ble-edged sword if MEK/ERK signaling is enhanced in HPV-infected tissues, potentially by
either intrinsic or extrinsic means (Fig 9B). Thereby, increased proliferation prevents differen-
tiation-induced late viral events, and increased dysplastic growth is promoted by both cellular-
and viral oncoprotein-mediated mechanisms. As demonstrated by studies analyzing HPV(+)
cervical and OP-SCCs [56,88], cell-intrinsic modes may include activating mutations in
upstream ERK activators, including EGFR/ERBB1, ERBB2, ERBB3, SRC, KRAS, NRAS, BRAF.
Extrinsic stimuli could include a wound response, or exposure to chemicals, pathogens, or
other inflammatory agents that activate the MEK/ERK pathway in the epithelium. For exam-
ple, we and other labs showed tobacco smoke components promote hr-HPV oncogene expres-
sion viaMEK and/or AP-1 TF activation [89–91]. Nitric oxide, a free radical involved in
cervical ripening during childbirth, activates ERK signaling [92]. We showed nitric oxide
enhances HPV oncogene expression and survival of mutagenized cells, providing a potential
mechanism by which multi-parity contributes to hr-HPV lesion progression [93]. Intracellular
Chlamydia trachomatis infections promote MEK/ERK signaling [94,95], and we predict this
could upregulate hr-HPV oncogene expression. Lastly, estrogen can activate ERK1/2 and
thereby AP-1 TFs via the G protein-coupled receptor homolog, GPER, which both catalyzes
the release of HB-EGF and signals through adenylyl cyclase (reviewed in [96]). Importantly,
epidemiological studies often consider these extrinsic exposures as co-factors with oncogenic
HPV infections promoting cancer progression [97], and, thus they may share the mechanism
of ERK activation by which they contribute to cell proliferation and hr-HPV oncogene expres-
sion, persistence and/or disease severity.
Perhaps our most significant, yet somewhat unexpected, finding is that suppressing MEK/
ERK signaling with pharmacological inhibitors has profound anti-viral effects on hr-HPV(+)
cells. Further, the inhibitors effectively quash hr-HPV oncogene transcription and protein
expression in both early neoplastic cells maintaining episomal genomes and in cancer cells
with integrated HPV genomes. This is particularly noteworthy since genetic means of sup-
pressing E6/E7 expression have shown these viral proteins are oncogenic drivers in vitro and
preclinical mouse tumor models. Reduction of E6/E7 expression restores tumor suppressor
functions, leads to apoptosis and/or senescence, and suppresses tumorigenicity in preclinical
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models [6,8,69,71,98]. However, genetic means to suppress HPV oncogenes are not yet partic-
ularly feasible in human studies. In contrast, many pharmacological inhibitors of MEK/ERK
are currently approved by the U.S. FDA for use in a variety of cancers unrelated to HPV infec-
tions. Importantly, we show that targeting cellular pathways usurped by and conserved among
HPVs is agnostic to hr-HPV genotypes, which is another major advantage over genetic
approaches that must be tailored specifically for each HPV gene and genotype targeted. Thus,
our work shows promise for clinical testing of clinically-approved inhibitors of MEK or ERK
to treat HPV early neoplastic lesions and cancers. As the AP-1 TF binding sites are highly con-
served across PV genomes, these inhibitors may well have anti-viral effects in other HPVs and
animal PVs that typically only cause benign tumors.
In summary, intracellular pathogens, particularly those that replicate in the cell nucleus
and/or rely on cellular proliferation, utilize host factors that are responsive to cellular signaling
cues. Many of these pathogens have evolved to alter cell signals to enhance their replication
and/or avoid immune recognition. Our work reveals that hr-HPV oncogene transcription
from replicating viral genomes in monolayer cells and epithelial tissues is governed by MEK/
ERK signaling. In addition, the control of oncogene expression by MEK/ERK signaling is
maintained in at least a subset of cancer cells bearing integrated HPV genomes. These observa-
tions suggest that HPVs have adapted their replicative cycles to regulate oncogene expression
in response to signaling pathways that guide the keratinocyte proliferation and differentiation.
We suggest this provides an opportunity to use molecular inhibitors that target cellular and tis-
sue factors to broadly impede pathogenic HPV infections. MEK or ERK inhibition in HPV-
transformed cancers may offer the benefit of anti-viral effects by reducing viral oncoprotein
activities and restoring tumor suppressor functions in addition to generally suppressing cellu-
lar proliferation; the former mechanisms may yield distinct advantages in treating HPV-posi-
tive cancers.
Materials and methods
Contact for reagent and resource sharing
Further information and requests for resources and reagents should be directed to by the lead
author, Michelle Ozbun (mozbun@salud.unm.edu).
Cell culture
The NIKS cell line (a gift from Paul Lambert, U. Wisc.-Madison) was derived from normal
immortalized human foreskin keratinocytes [44]. NIKS-SG3 and the NIKS-1K cell lines (gifts
from P. Lambert and John Doorbar, U. Cambridge, respectively) were created by transfection
of circular, wild-type HPV16 genomes into NIKS cells, resulting in stable, episomally replicat-
ing viral genomes [45,46]. NIKS-SG3 cells maintain�50–100 copies of HPV16 per cell [45];
NIKS 1K cells maintain�200 copies of HPV16 per cell [46]. Similarly, NIKS-H18 cells were
created by transfection of circular, wild-type HPV18 genomes into NIKS cells (a gift from
John Doorbar). Cell lines W12-E (a gift from P. Lambert) and CIN-612 9E (a gift from Laimo-
nis Laimins, Northwestern U.) were established from human cervical intraepithelial neoplasia
grade 1 (CIN1) biopsies. W12-E cells (clone 20863) maintain episomal HPV16 genomes at
�100 copies per cell [99,100]. CIN-612 9E cells maintain episomal HPV31 (subtype 31b)
genomes at 500–100 copies per cell [101]. W12-E and CIN-612 9E cells were investigated at
<30 passages after cloning. All keratinocyte cell lines were co-cultured with mitomycin C-
treated J2-3T3 fibroblast feeder cells in E medium containing 10% fetal bovine serum (FBS;
Atlanta Biologicals) and 10 ng/ml murine epidermal growth factor (EGF; Corning) as
described previously [93,102]. J2-3T3 fibroblasts were propagated in high-glucose DMEM
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(Irvine Sci.) supplemented with 10% newborn calf serum (NCS, Hyclone), 2mM glutamine.
Fibroblasts were treated with 24 μM mitomycin C (Sigma) for 2–4 h followed by washing 3x
each with� 5 ml of 1X phosphate buffered saline (PBS). The UM-SCC-47 cell line (a gift from
Thomas Carey, U. Michigan), established from an OP-SCC of the lateral tongue [66], was
grown in DMEM plus 10% FBS. Cell lines were authenticated by short tandem repeat analysis
(IDEXX) and used within 15 passages of verification. For all experiments, keratinocytes were
plated without feeder cells in E medium with 10% FBS; UM-SCC-47 cells were plated in
DMEM with 10% FBS.
Organotypic 3D-epithelial tissue cultures and immunohistochemistry (IHC)
Cells were expanded and grown as organotypic epithelial tissues at the air-medium interface
with E medium plus 10% FBS as detailed [102,103]. Growing epithelial tissues were treated
every 2nd day with 20 mM 1,2-dioctanoyl-sn-glycerol (C8:0; Calbiochem). For some experi-
ments, cultures were also treated with 10 ng/ml EGF, 0.1% dimethyl sulfoxide (DMSO;
Thermo-Fisher), or 10 nM Trametinib in DMSO every 2nd day beginning on day 8. After 14
days of growth, tissues were fixed in 10% neutral buffered formalin for 24h, room temperature,
then embedded in paraffin (FFPE). Tissue sections (4 μm thick) were subject to hematoxylin
and eosin (H&E) staining, RNA ISH or IHC. For IHC, antigens were unmasked by boiling in
10mM sodium citrate with 0.05% Tween-20 in a BioSB Tintoretriever pressure chamber for 15
min, 100˚C, cooling to room temperature, and washing in PBS, then a 10-min H2O2 wash. For
IHC detection of phospho (p)-ERK1/2, blocking was in 5% normal goat serum in TBS-T for 1
h at room temperature. Rabbit anti-p-p44/42 MAPK (T202/Y204) (Cell Signaling) was used at
a 1:2000 dilution. Primary antibodies were applied in Signal Stain antibody diluent (Cell Sig-
naling) and incubated overnight, 4˚C. The sections were washed with TBS-T and subject to
Signal Stain Boost Detection Reagent (Cell Signaling) and Signal Stain DAB (diaminobenzi-
dine) Chromogen using the manufacturer’s recommendations. p16INK4A was detected using
a mouse monoclonal antibody at 1:200 (Calbiochem) and performed by the UNM Cancer
Center’s Human Tissue Repository Shared Resource. Organotypic tissue data were confirmed
in independent experiments.
Tumor Microarray (TMA) Immunohistochemical staining and scoring
Tissue specimens from 250 patients with cervical intraepithelial neoplasia (CIN) and 330 nor-
mal epithelium tissues were constructed into Tissue microarrays (TMAs) as previously
described [29]. Paraffin blocks were provided by the Korea Gynecologic Cancer Bank through
Bio & Medical Technology Development Program of the Ministry of Education, Science and
Technology, Korea (NRF-2017M3A9B8069610). This study was approved by the Institutional
Review Board of Gangnam Severance Hospital (Seoul, South Korea), and all procedures were
conducted in accordance with the guidelines of the Declaration of Helsinki.
The TMA sections were deparaffinized, rehydrated, and subjected to heat-induced antigen
retrieval using antigen retrieval buffer of pH 6.0 (for p-ERK1/2) or pH 9.0 (for p16INK4)
(Dako, Carpinteria, CA). All slides were quenched for 10 min in 3% H2O2 to block for endoge-
nous peroxidase. The sections were incubated with primary antibodies against p-ERK1/2 (Cell
Signaling; clone #20G11; 1:200 dilution) and p16INK4 (BD Pharmingen; clone #G175-405;
1:1000 dilution) for 1 hr at room temperature. The antigen-antibody reaction was visualized
with the Dako EnVision+ Dual Link System-HRP (Dako) and DAB+ (3, 3’-diaminobenzidine;
Dako). The slides were lightly counterstained with hematoxylin and then reviewed by light
microscopy. The control included immunoglobulin G (IgG) and omission of the primary
antibody.
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The stained TMA sections were digitized using the NanoZoomer 2.0 HT (Hamamatsu Pho-
tonics K.K., Japan) at ×20 objective magnification. Digital analysis of the images was per-
formed using Visiopharm Integrator System v6.5.0.2303 (VIS; Visiopharm, Hørsholm,
Denmark). The mean intensity of DAB for each defined image was measured for quantifica-
tion, and was categorized as follows: 0 = negative, 1 = weak, 2 = moderate, and 3 = strong. The
final immunostaining score was calculated by multiplying the staining intensity and percent-
age of positive cells (possible range 0–300). The TMA contains 253 cases of cervical intrae-
pithelial neoplasia, however, due to the complexity of sectioning, staining, as well as the
heterogeneity of the samples, only 249 and 224 samples could be interpreted for the p16INK4
and pERK1/2, respectively.
Nucleic acid collection and analyses
RNA and DNA were extracted from cells with TriReagent (Sigma) per the manufacturer’s
directions. RNA was DNase treated (TURBO DNA-free kit, Ambion). Reverse transcription
(RT) of total RNAs (0.5 μg each) was performed at 42˚C, 60 min. Viral and cellular transcripts
were subject to quantitative polymerase chain reaction (qPCR) on cDNAs as previously
reported [93]; qPCR primers are summarized in S1 Table and illustrated in S1 Fig. The HPV
transcripts targeted included unspliced E6 and E7 ORFs (Bio-Rad SsoFast EvaGreen Super-
mix) and spliced E1^E4 mRNA that also contains the E5 ORF (E1^E4/E5) (Bio-Rad iQ Super-
mix) (see S1 Fig). PCR for cDNA of FOS, JUN, JUNB was performed with PrimePCR PreAmp
for SYBR Green Assay (BioRad). RT-qPCR data for target mRNAs were normalized to ribo-
somal protein 18s mRNA levels (Bio-Rad iQ Supermix) performed on the same cDNAs. qPCR
was performed on a Bio-Rad CFX96 and analyzed using Bio-Rad CFX Manager
(version1.6.541.1068).
RNA in situ hybridization (ISH)
Cells grown on chamber slides and FFPE raft tissue sections were fixed in 10% NBF. Cells and
tissues were stained according to the manufacturer’s protocol (2.5 HD Detection Kit–Brown)
using a probe to hr-HPV RNAs containing the E6/E7 open reading frames (HPV HR7 probe,
Advanced Cell Diagnostics). Signal detection was performed with ACD DAB. Tissues were
counterstained with 50% Gill’s hematoxylin solution number 1. The specificity of RNA ISH
was determined by RNase treatment.
Protein isolation and immunoblotting
Cells were lysed on ice in RIPA buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.1%
SDS, 5 mM EDTA, 1% deoxycholic acid) supplemented with 1X HALT protease/phosphatase
inhibitor (Pierce), and 0.2mM sodium orthovanadate. For detection of HPV16 E6, cells were
extracted in 1X lysis buffer (43.9mM HEPES, pH 7.5; 131.7mM NaCl; 1.1% Triton X-100;
8.8% glycerol; 1x protease inhibitor cocktail; 1mM PMSF; 1mM EGTA). Samples were centri-
fuged at 12K x g for 10 min at 4˚C and supernatants transferred to fresh tubes. Protein concen-
trations were determined by Bradford assay (Bio-Rad Protein Reagent). Sample loading buffer
(6X) (62.5 mM Tris-HCl pH 6.8, 2% sodium dodecyl sulfate, 40% glycerol, 0.05% bromophe-
nol blue) with 0.05% β-mercaptoethanol was added to samples (1X final concentration). Total
proteins (typically 25–50 μg) were subjected to 4–12% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). Proteins were transferred to Immobilon-P PVDF membrane
(Bio-Rad) using immunoblot transfer buffer (0.25 M Tris, 0.192 M glycine, 20% methanol).
Membranes were blocked with bovine serum albumin in Tris-buffered saline-Tween-20
(TBS-T; 20 mM Tris, 137 mM NaCl, 0.1% Tween-20) and incubated with primary antibodies
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overnight at 4˚C. Antibodies purchased from Cell Signaling: p-EGFR (Y845) and EGFR, p-
p44/42 MAPK (Y292, Y204), p44/42 MAPK, p-AKT, AKT, c-Fos, c-Jun, JunB, p53, and
p16INK4a were used according to manufacturer’s recommendations. HRP-conjugated anti-
mouse and anti-rabbit secondary antibodies (Cell Signaling or GE Healthcare) were used at a
1:5000 dilution. Membranes were stripped using mild PVDF stripping buffer (399.6 μM gly-
cine, 3.5 μM SDS, 1% Tween 20, pH 2.2) for 8 min at room temperature followed by extensive
washing in TBS-T. Stripped blots were re-blocked as described above then re-probed for β-
actin as a loading control. To detect HPV16 E6 protein, 300μg of total protein lysate was sub-
jected to SDS-PAGE and transferred to Immobilon-P PVDF membrane at 400mA, 90 min.
Membranes were blocked overnight, 4˚C then probed using an E6 antibody (Arbor Vita) at
5 μg/ml for 1 h, room temperature. The membrane was washed and secondary goat anti-
mouse IgG-HRP (Jackson ImmunoResearch). Blots were visualized on a Bio-Rad ChemiDoc
station or Konica SRX-101A film processor (Diagnostic Imaging Inc.) and analyzed with Fiji
{Schindelin,2012}). All IB results were confirmed in�3 independent experiments.
Flow cytometry
Keratinocytes were seeded without fibroblast feeder cells in E medium plus 10% FBS (lacking
EGF) and allowed to attach overnight. Cells were dissociated using 0.25% trypsin-EDTA
(Sigma), 20 min. Trypsin was quenched with complete E medium and cells were pelleted and
washed with 2 ml cold 1X PBS. Cells were resuspended in 100 μl of cold 1x PBS and incubated
with 2 μg AlexaFluor-647 labeled anti-EGFR antibody R-1 (Santa Cruz Biotech.) for 30 min,
4˚C with mixing. Antibody binding beads from Quantum Simply Cellular kit (Bangs Labs.)
were labeled concurrently for each experiment. Cells and beads were each washed and resus-
pended according to the manufacturer’s directions. Fluorescence signal was detected using a
BD LSR Fortessa flow cytometer; data were analyzed using FACS DIVA software.
Kinase inhibitors
Erlotinib, Trametinib, SCH772984 and BYL719 (Selleck) were reconstituted in DMSO. Dose-
response curves were generated for each inhibitor to determine effective concentrations in cell
lines.
AP-1 transcription factor activity
W12-E cells were seeded at 1.3 x105 cells/cm2 in a 6-well plate and allowed to adhere overnight.
The cells were pretreated with DMSO or Trametinib for 8h prior to stimulation with 10 ng/ml
EGF. Nuclear extracts were obtained using the Nuclear Extract Kit (Active Motif) following
the manufacturer’s protocol. Active AP-1 transcription factors levels were measured using
5 μg of nuclear extract and following manufacturer protocol for the TransAM AP-1 Family
ELISA (Active Motif).
Transfection-mediated siRNA knockdown
W12-E cells were seeded at 1.49x104 cells/cm2 in a 12 well plate format and allowed to adhere
overnight. The cells were starved for 4 h with Opti-MEM (Gibco) to improve transfection effi-
ciencies. Cells were transfected in Opti-MEM with 25 nM of ON-Target siRNA pools targeting
FOS, JUN or JUNB transcripts (Horizon Discovery) and 1 ul of DharmaFECT 1 Transfection
Reagent (Horizon Discovery). After 24 h the cells were harvested for protein and RNA or the
medium was changed to complete E medium containing 10% calf serum and the cells were
incubated for an additional 24 h before harvesting.
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Statistical analyses
All statistical analyses for growth curves and RT-qPCR experiments were performed in Graph-
Pad Prism 8.0.1. For each replicate the viral targets were normalized to ribosomal protein 18s
mRNA per experiment. Analyses of protein fold changes over time (Fig 3C) employed the ran-
dom effects linear regression model with random slope. Analyses of the relative RNA levels
with increasing cell density or drug treatment were based on the parametric 1-way Welch’s
ANOVA with Dunnett’s T3 multiple comparison test. Analyses of RT-qPCR data from EGF-
treated or untreated cells were compared by Welch’s t-test. Probability (p) values of less than
0.05 were considered to be statistically significant.
TMA IHC data were analyzed using IBM SPSS statistics version 21 (IBM Corporation,
Armonk, NY). IHC cut-off for high expression of p-ERK1/2 and p16INK4 was determined
through the receiver operating characteristic (ROC) analysis. The statistical comparisons of
the differences in the protein expressions in the different groups were performed using non-
parametric statistics (Kruskal-Wallis/Mann–Whitney U). Chi-square test was used to perform
statistical comparisons for categorical variables. Correlation between protein expression was
determined by Pearson’s (χ2 = 212.658, p<0.001). Results with two-tailed p values less than
0.05 were considered statistically significant.
Supporting information
S1 Fig. Organization of HPV16 and HPV31 genomes indicating general structures of the
polycistronic early transcripts. Related to Figs 2–6 and 9, S2 and S1 Table. The circular
genome of�7900 base pairs is linearized at the late polyadenylation (polyA) signal to illustrate
the regulatory long control region (LCR), open reading frames, and main early mRNAs (A-E).
Nucleotide numbering is below the thin horizontal rule (based on HPV16 [GenBank accession
number: K02718], HPV31 [GenBank accession number: J04353]. Bent arrows mark the major
early and late promoters; circles denote EGFR-responsive AP-1 transcription factor binding sites
(AP-1 BS) [33]. Early and late polyA sites are indicated. Shaded boxes illustrate ORFs located in
all three reading frames for each viral genome aligned with the polycistronic early transcripts
(A-E). Each of the primer pairs for qPCR is represented by a node and the products as lines con-
necting each primer node. Long vertical lines demark the boundaries of the ORFs and the E6�
and E1^E4 introns are shaded. Note that when the amplification products span introns, only
spliced RNAs are amplified as the PCR cycle profile does not amplify>200 bp (verified by gel
electrophoresis). The specificity of the products and their sizes is given for each (LCR, E6, E7,
E1^E4). (A-E) Thick black lines represent noncoding sequences and thin lines mark introns.
(TIFF)
S2 Fig. Increasing cell density reduces global tyrosine phosphorylation, EGFR/ERK signal-
ing and HPV oncogene expression. Related to Fig 3. (A-B) Plates of decreasing surface area
(21cm2, 9.0cm2 and 4.6cm2) were seeded with 1.25x106 NIKS-SG3 cells that were allowed to
grow for 24h. (A) Crystal violet staining shows increasing cell density from left to right
(wedge). (B) Protein lysates were collected 24h post seeding of HPV16(+) cells (NIKS-SG3,
NIKS-1K, W12-E), HPV18(+) cells (NIKS-HPV18), and HPV31(+) cells (CIN-612 9E).
Lysates were subjected to SDS-PAGE and IB for total phospho-tyrosine and actin. (C-D)
Experimental details as in Fig 3D–3F and S2A Fig. Antibodies recognizing HPV31 E6 and E7
proteins are not available. (E) W12-E cells subject to experimental details as in Fig 2G and Fig
2H. (F) CIN-612 9E cells analyzed for HPV31 E7 mRNAs as described for HPV16 in Fig 1A
with experimental details as in Fig 3G and 3H. Scatterplots represent the mean and range of
the data from 3 independent experiments. Analysis using 1-way ANOVA with Dunnett’s T3
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multiple comparison test (�p<0.05, ��p<0.01 or n.s., not significant). (G) Flow cytometry
quantification of the number of plasma membrane-resident EGFR proteins on each cell line in
subconfluent states. Scatterplots represent the center tendency and variability of the data (n.s.,
no significant differences compared to NIKS cells; analyzed by 1-way ANOVA with Tukey’s
post hoc test).
(TIFF)
S3 Fig. PI3K pathway inhibition does not impact HPV16 oncoprotein restoration after
EGF stimulation. Contact inhibited W12-E cells were grown in the presence of various doses
of an inhibitor of p110α (10 nM, 100 nM, 1 μM or 10 μM BYL719) for 8h. Cells were stimu-
lated for 14h with 10ng/ml of EGF before the harvesting of protein for SDS-PAGE and IB.
(TIFF)
S1 Table. p-ERK1/2 and p16INK4 expressiona in human cervical intraepithelial neoplasia
(related to Fig 1).
(DOCX)
S2 Table. Primers used in analysis of HPV transcription and genome copies.
(DOCX)
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AP-1 and AP-1 regulatory genes during HPV-induced carcinogenesis. Cellular Oncology. 2008; 30
(1):77–87. https://doi.org/10.1155/2008/279656 PMID: 18219112
63. Evans MF, Peng Z, Clark KM, Adamson CS-C, Ma X-J, Wu X, et al. HPV E6/E7 RNA in situ hybridiza-
tion signal patterns as biomarkers of three-tier cervical intraepithelial neoplasia grade. PLoS One.
2014; 9(3):e91142. https://doi.org/10.1371/journal.pone.0091142 PMC3953338. PMID: 24625757
64. Stein AP, Swick AD, Smith MA, Blitzer GC, Yang RZ, Saha S, et al. Xenograft assessment of predic-
tive biomarkers for standard head and neck cancer therapies. Cancer Med. 2015; 4(5):699–712.
https://doi.org/10.1002/cam4.387 PMID: 25619980
65. Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, et al. Genome-wide analysis of HPV inte-
gration in human cancers reveals recurrent, focal genomic instability. Genome Res. 2014; 24(2):185–
99. https://doi.org/10.1101/gr.164806.113 PMID: 24201445
66. Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, et al. P53 mutation correlates with cis-
platin sensitivity in head and neck squamous cell carcinoma lines. Head Neck. 2003; 25(8):654–61.
https://doi.org/10.1002/hed.10274 PMID: 12884349
67. Kalele K, Kulkarni N, Kathariya R. Oral Squamous Cell Carcinoma: Hematoxylin and Eosin Staining. J
Clin Diag Res. 2015; 9(9):ZJ01. https://doi.org/10.7860/JCDR/2015/13644.6416 PMC4606365.
PMID: 26501036
68. Sima N, Wang W, Kong D, Deng D, Xu Q, Zhou J, et al. RNA interference against HPV16 E7 onco-
gene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of
Rb and p53. Apoptosis. 2008; 13(2):273–81. https://doi.org/10.1007/s10495-007-0163-8 PMID:
18060502
69. Hsu DS, Kornepati AV, Glover W, Kennedy EM, Cullen BR. Targeting HPV16 DNA using CRISPR/
Cas inhibits anal cancer growth in vivo. Future Virol. 2018; 13(7):475–82. https://doi.org/10.2217/fvl-
2018-0010 PMID: 30245733
70. Hu Z, Yu L, Zhu D, Ding W, Wang X, Zhang C, et al. Disruption of HPV16-E7 by CRISPR/Cas system
induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. BioMed Res
Int. 2014; 2014(3):612823–9. https://doi.org/10.1155/2014/612823 PMC4127252. PMID: 25136604
71. Zhen S, Hua L, Takahashi Y, Narita S, Liu Y-H, Li Y. In vitro and in vivo growth suppression of human
papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochem Biophys Res Comm.
2014; 450(4):1422–6. https://doi.org/10.1016/j.bbrc.2014.07.014 PMID: 25044113
72. Carter SB. Tissue homeostasis and the biological basis of cancer. Nature. 1968; 220(5171):970–4.
https://doi.org/10.1038/220970a0 PMID: 5701853
73. Abercrombie M. Contact Inhibition and Malignancy. Nature. 1979; 281(5729):259–62. https://doi.org/
10.1038/281259a0 PMID: 551275
74. Miettinen PJ, Berger JE, Meneses J, Phung Y, Pedersen RA, Werb Z, et al. Epithelial immaturity and
multiorgan failure in mice lacking epidermal growth factor receptor. Nature. 1995; 376(6538):337–41.
https://doi.org/10.1038/376337a0 PMID: 7630400
75. Murillas R, Larcher F, Conti CJ, Santos M, Ullrich A, Jorcano JL. Expression of a dominant negative
mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alter-
ations in hair follicle development and skin structure. EMBO J. 1995; 14(21):5216–23. PMC394631.
PMID: 7489711
76. Pasonen-Seppanen S, Karvinen S, Torronen K, Hyttinen J, Jokela T, Lammi MJ, et al. EGF upregu-
lates, whereas TGF-beta downregulates, the hyaluronan synthases has2 and has3 in organotypic ker-
atinocyte cultures: Correlations with epidermal proliferation and differentiation. J Invest Dermatol.
2003; 120(6):1038–44. https://doi.org/10.1046/j.1523-1747.2003.12249.x PMID: 12787132
77. Akerman GS, Tolleson WH, Brown KL, Zyzak LL, Mourateva E, Engin TSW, et al. Human Papillomavi-
rus Type 16 E6 and E7 Cooperate to Increase Epidermal Growth Factor Receptor (EGFR) mRNA Lev-
els, Overcoming Mechanisms by which Excessive EGFR Signaling Shortens the Life Span of Normal
Human Keratinocytes. Cancer Res. 2001; 61(9):3837–43. PMID: 11325860
PLOS PATHOGENS MEK/ERK regulates hr-HPV oncogene expression
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009216 January 22, 2021 28 / 30
78. Hu G, Liu W, Mendelsohn J, Ellis LM, Radinsky R, Andreeff M, et al. Expression of epidermal growth
factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer
Inst. 1997; 89(17):1243–6. https://doi.org/10.1093/jnci/89.17.1243 PMID: 9293908
79. Crusius K, Auvinen E, Steuer B, Gaissert H, Alonso A. The Human Papillomavirus Type 16 E5-Protein
Modulates Ligand-Dependent Activation of the EGF Receptor Family in the Human Epithelial Cell Line
HaCaT. Exp Cell Res. 1998; 241(1):76–83. https://doi.org/10.1006/excr.1998.4024 PMID: 9633515
80. Crusius K, Rodriguez I, Alonso A. The human papillomavirus type 16 E5 protein modulates ERK1/2
and p38 MAP kinase activation by an EGFR-independent process in stressed human keratinocytes.
Virus Genes. 2000; 20(1):65–9. https://doi.org/10.1023/a:1008112207824 PMID: 10766308
81. Straight SW, Hinkle PM, Jewers RJ, McCance DJ. The E5 oncoprotein of human papillomavirus type
16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in ker-
atinocytes. J Virol. 1993; 67(8):4521–32. https://doi.org/10.1128/JVI.67.8.4521-4532.1993 PMID:
8392596
82. Wetherill LF, Holmes KK, Verow M, Müller M, Howell G, Harris M, et al. High-risk human papillomavi-
rus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors. J Virol.
2012; 86(9):5341–51. https://doi.org/10.1128/JVI.06243-11 PMC3347351. PMID: 22357280
83. Rosenberger S, Arce JD-C, Langbein L, Steenbergen RDM, Rösl F. Alternative splicing of human pap-
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